Answers are grounded in this paper and cite their sources.
Background Fragmented referral pathways, incomplete clinical data, and unequal access to modern therapies challenge breast cancer care in many resource-constrained settings. The Chiang Mai Cancer Registry (CMCR) was expanded into a comprehensive clinical registry within the Suandok Breast Cancer Network (SBCN), a regional breast cancer care network in Northern Thailand. Methods We conducted a retrospective cohort study of patients diagnosed with invasive breast cancer within the SBCN between January 2016 and December 2020. Clinical, pathological, and treatment data, including molecular subtypes, surgery, systemic therapy, and radiotherapy, were extracted from electronic medical records. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results A total of 2,417 patients were included. HR and HER2 status were available in 94.3% of cases, compared with 79.6% in our earlier cohorts. The most common subtype was HR+/HER2− (56.6%), followed by triple-negative breast cancer (14.5%), HR−/HER2+ (13.3%), and HR+/HER2+ (9.9%). Among 564 HER2-positive patients, 59.8% received adjuvant trastuzumab. At a median follow-up of 80.1 months, survival rates differed significantly by subtype. HR+/HER2− patients had the most favorable outcomes (5-year DFS 80.6%, OS 82.0%), whereas triple-negative breast cancer (TNBC) patients had the poorest outcomes (DFS 69.1%, OS 70.5%). Among HER2-positive patients, trastuzumab use was associated with improved DFS (80.4% vs. 65.9%). Conclusions A comprehensive clinical registry improved data completeness and enabled robust evaluation of treatment patterns and outcomes. Increased access to HER2-targeted therapy and favorable survival outcomes highlight continued progress in coordinated breast cancer care within a regional healthcare network.
No takes yet. Share an insight, caveat, or question.
Chitapanarux et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: